🇺🇸 Daunorubicin, Cytarabine in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Myeloid Leukaemia Recurrent — 1 report (10%)
  2. Allogenic Stem Cell Transplantation — 1 report (10%)
  3. Drug Eruption — 1 report (10%)
  4. Drug Hypersensitivity — 1 report (10%)
  5. Febrile Neutropenia — 1 report (10%)
  6. Haemodialysis — 1 report (10%)
  7. Hypotension — 1 report (10%)
  8. Nephropathy Toxic — 1 report (10%)
  9. Off Label Use — 1 report (10%)
  10. Staphylococcal Infection — 1 report (10%)

Source database →

Daunorubicin, Cytarabine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Daunorubicin, Cytarabine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Daunorubicin, Cytarabine in United States?

The First Hospital of Jilin University is the originator. The local marketing authorisation holder may differ — check the official source linked above.